Development of a stability-indicating RP-UPLC method for simultaneous determination of Abemaciclib and Olaparib with LC–MS characterization of degradation products and in vitro performance evaluation
Journal of Chromatographic Science · 23.07.2026 · 64 (7)
DOI: 10.1093/chromsci/bmag022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Chromatographic Science, online erschienen am 23.07.2026. Verfasst von Sathish Kumar Konidala und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, School of Biotechnology and Pharmaceutical Sciences, Vignan's Foundation for Science, Technology, and Research…. Hauptthemen laut MEDLINE: Piperazines, Phthalazines, Aminopyridines, Chromatography, Reverse-Phase. Die Arbeit nennt 26 Literaturangaben. Gefördert von: Vignan's Foundation for Sciences, Technology and Research (Deemed to be University), Vignan’s Foundation for Sciences, Technology and Research.
Abstract (Originalsprache)
The simultaneous determination of Abemaciclib and Olaparib in in-houseprepared tablets was accomplished by the development and validation of a novel and rapid and sensitive reverse-phase ultra-performance liquid chromatography (RP-UPLC) technique. Using a Waters X-Bridge C18 (4.6 × 100 mm, 3.5 μm) column and a mobile phase made up of 0.1% orthophosphoric acid in water, acetonitrile and methanol (70:20:10% v/v/v) in an isocratic elution mode at a flow rate of 1 mL/min, the chromatographic separation was accomplished. High sensitivity and selectivity were made possible by performing the detection at 219 nm. Following ICH Q2(R1) criteria, the technique was validated and showed high linearity (R2 > 0.999) for both drugs over the concentration range of 10–60 μg/mL. Within acceptable boundaries (<2% Relative Standard deviation (RSD)), both intra-day and inter-day precision and accuracy (recovery percentage) were proven. Forced degradation studies confirmed the method’s stability-indicating capability, Stability studies indicated significant degradation under acid, alkali, peroxide and thermal degradation conditions. The degradation products were characterized by LC–MS technique, and possible degradation pathways were proposed. Additionally, in vitro pharmacokinetic evaluation, including dissolution and drug release kinetics, was performed to assess formulation performance. The developed method proved simple, precise and robust, making it suitable for routine quality control, stability study and pharmacokinetic studies of Abemaciclib and Olaparib co-formulated tablets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, School of Biotechnology and Pharmaceutical Sciences, Vignan's Foundation for Science, Technology, and Research, Guntur 522213, Vadlamudi, Andhra Pradesh, India.
- Department of Pharmaceutical Analysis, Vignan Pharmacy College, Vadlamudi, Guntur 522213, Andhra Pradesh, India.
ORCID-Profile: Sathish Kumar Konidala
Förderung
- Vignan's Foundation for Sciences, Technology and Research (Deemed to be University)
- Vignan’s Foundation for Sciences, Technology and Research
Zitieren
APA
Konidala, S. K., Grandhi, S., & Kamma, H. S. (2026). Development of a stability-indicating RP-UPLC method for simultaneous determination of Abemaciclib and Olaparib with LC–MS characterization of degradation products and in vitro performance evaluation. Journal of Chromatographic Science, 64(7). https://doi.org/10.1093/chromsci/bmag022
Vancouver
Konidala SK, Grandhi S, Kamma HS. Development of a stability-indicating RP-UPLC method for simultaneous determination of Abemaciclib and Olaparib with LC–MS characterization of degradation products and in vitro performance evaluation. Journal of Chromatographic Science. 2026;64(7). doi:10.1093/chromsci/bmag022
BibTeX
@article{Konidala2026,
author = {Konidala, Sathish Kumar and Grandhi, Srikar and Kamma, Harsha Sri},
title = {Development of a stability-indicating RP-UPLC method for simultaneous determination of Abemaciclib and Olaparib with LC–MS characterization of degradation products and in vitro performance evaluation},
journal = {Journal of Chromatographic Science},
year = {2026},
volume = {64},
number = {7},
doi = {10.1093/chromsci/bmag022}
}
EUVIMED